Neurology Specific Literature Search   
 
[home][thesaurus]
    
Click Here to return To Results

 

Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset, The ATLANTIS Study:A Randomized Controlled Trial
JAMA 282:2019-2026, Clark,W.M.,et al, 1999
See this aricle in Pubmed

Article Abstract
This study found no significant rt-PA benefit on the 90-day efficacy end points in patients treated between 3 and 5 hours. The risk of symptomatic ICH increased with rt-PA treatment. These results do not support the use of intravenous r t-PA for stroke treatment beyond 3 hours.
 
Related Tags
(click to filter results - removes previous filter)

adverse drug reaction
cerebrovascular accident
cerebrovascular accident,acute management of
cerebrovascular accident,thrombolytic agents in treatment
fibrinolytic agents
fibrinolytic agents,complications
iatrogenic neurologic disorders
intracerebral hemorrhage
mortality
tissue plasminogen activator,intravenous
treatment of neurologic disorder

Click Here to return To Results